Progyny (PGNY) Is Down 14.3% After Q2 Beat, Buyback Completion And Raised 2026 Guidance
- Progyny’s recent news includes reporting second-quarter 2026 results with higher revenue and net income than a year earlier, confirming new earnings guidance for the third quarter and full year 2026, completing a US$57.5 million buyback of 2,000,000 shares announced in May, and participating in Canaccord Genuity’s annual growth conference on August 11, 2026.
- The combination of stronger profitability, updated 2026 revenue and earnings projections, and active share repurchases underscores management’s confidence in Progyny’s business trajectory and capital allocation priorities.
- Next, we’ll examine how Progyny’s upgraded 2026 guidance and completed share repurchase program influence the company’s investment narrative.
AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Progyny Investment Narrative Recap
To own Progyny, you need to believe employer demand for fertility and family-building benefits will stay resilient and that the company can keep converting that demand into profitable growth. Right now, the key near term catalyst is management’s ability to hit or refine 2026 guidance, while the biggest risk is employer benefit cost-cutting. The latest earnings beat, reaffirmed guidance, and buybacks appear supportive, but do not remove that underlying demand risk.
The updated 2026 outlook, with projected full year revenue of US$1.360 billion to US$1.385 billion and net income of US$104.8 million to US$109.9 million, is the most directly relevant piece of news. It gives investors a clearer near term bar for how well Progyny is managing client transitions and underlying demand, which ties closely to both the upside catalyst of consistent execution and the downside risk of slower employer adoption or reduced benefit budgets.
Yet even with stronger guidance, investors should still be aware of how quickly employer priorities could shift if...
Read the full narrative on Progyny (it's free!)
Progyny's narrative projects $1.6 billion revenue and $153.7 million earnings by 2029. This requires 7.9% yearly revenue growth and a $75.1 million earnings increase from $78.6 million today.
Uncover how Progyny's forecasts yield a $33.82 fair value, a 31% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue of about US$1.7 billion and earnings near US$189 million by 2029, which is far more upbeat than the baseline view, so this new guidance and utilization risk could push you to reassess where you sit along that spectrum of expectations.
Explore 4 other fair value estimates on Progyny - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Progyny research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Progyny research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Progyny's overall financial health at a glance.
Ready For A Different Approach?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com